Jirjees Feras, Saad Ali K, Al Hano Zahraa, Hatahet Taher, Al Obaidi Hala, Dallal Bashi Yahya H
College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates.
College of Medicine and Health Sciences, United Arab Emirates University, Alain, United Arab Emirates.
Infect Dis Rep. 2021 Apr 1;13(2):259-284. doi: 10.3390/idr13020029.
SARS-CoV-2 (COVID-19) has been changing the world since December 2019. A comprehensive search into many COVID-19 treatment guidelines was conducted and reported in this article. This is a review paper to probe differences in COVID-19 managing strategies and explore the most common treatment plans among countries. Published guidelines from 23 countries and three references guidelines-until the end of 2020-were included in this article. The majority of COVID-19 treatment options were reported in this review and it includes antiviral drugs, antimalarial drugs, antibiotics, corticosteroids, immunotherapy, anticoagulants, and other pharmacological treatment. The presence of such information from different countries in a single comprehensive review article could help in understanding and speculation of variation in the recommended treatment in each country. This might be related to the cost of medications, the access to the medications, availability of medication that could potentially be useful in managing COVID-19 cases, and the availability/capacity of healthcare facilities. Finally, although there are various treatment groups listed in the published therapeutic guidelines worldwide, unfortunately, there is no evidence for effectiveness of most of these medications in reducing the COVID-19 mortality curve over more than one year of this global pandemic.
自2019年12月以来,严重急性呼吸综合征冠状病毒2(SARS-CoV-2,即新冠病毒)一直在改变着世界。本文对诸多新冠治疗指南进行了全面检索并予以报道。这是一篇综述文章,旨在探究新冠管理策略的差异,并探索各国最常见的治疗方案。本文纳入了截至2020年底来自23个国家发布的指南以及3份参考文献指南。本综述报道了大多数新冠治疗选择,包括抗病毒药物、抗疟药物、抗生素、皮质类固醇、免疫疗法、抗凝剂及其他药物治疗。在一篇综合性综述文章中呈现来自不同国家的此类信息,有助于理解和推测各国推荐治疗方法的差异。这可能与药物成本、药物可及性、可能对管理新冠病例有用的药物的可得性以及医疗设施的可及性/能力有关。最后,尽管全球已发布的治疗指南中列出了各种治疗组,但遗憾的是,在这场全球大流行的一年多时间里,没有证据表明这些药物中的大多数在降低新冠死亡率方面有效。